Fondaparinux:A cornerstone drug in acute coronary syndromes

作     者：Mohammed Yunus Khan Chandrashekhar K Ponde Viveka Kumar Kumar Gaurav 

作者机构：Medical AffairsDr.Reddy's Laboratories LtdHyderabad 500018India Department of CardiologyP.D.Hinduja Hospital&Medical Research CentreMumbai 400016India Department of CardiologyMax Super Speciality HospitalNew Delhi 110017India 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)

年 卷 期：2022年第14卷第1期

页      面：40-53页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Acute coronary syndrome Anti-coagulant therapy Antiplatelet therapy Fondaparinux Unfractionated heparin Enoxaparin 

摘      要：In acute coronary syndrome(ACS),the use of anticoagulants in conjunction with antiplatelet agents in the acute phase has resulted in reduced ischemic events and is more effective than either class of drug used *** parenteral anticoagulation is essential at the time of diagnosis,a balance must be made between ischemic benefit and the increased risk of bleeding when prescribing *** events associated with anticoagulants,such as heparin-induced thrombocytopenia,bleeding problems,and the need for close monitoring of anticoagulant activity,have contributed to finding agents that reduce these *** like the Organization to Assess Strategies in Ischemic Syndromes 5 and 6 and their meta-analysis have proven the efficacy of Fondaparinux over the entire ACS *** convenience of administration(once daily),lack of monitoring,reduction in mortality,and better safety profile make Fondaparinux a simple and effective anti-coagulant for the management of ACS.